The Advanced Therapy Medicinal Products CDMO Market Size is valued at 5.88 Billion in 2023 and is predicted to reach 14.58 Billion by the year 2031 at a 12.12 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The demand for personalized treatment strategies is a significant driver for the advanced therapy medicinal products market.
- Targeted sequencing offers opportunities to detect cancer-related mutations, driving its application in oncology and personalized cancer treatment.
- North America dominated the market and accounted for a global revenue share in 2023.
- The complexity of interpreting vast amounts of genomic data generated by sequencing platforms presents a significant challenge for the advanced therapy medicinal products market.
Advanced therapy medicinal products are a class of human-use biological products that include gene therapy, cell therapy, and tissue-engineered products. The expanding clinical studies of ATMP and rising awareness and belief among researchers about the benefits of advanced treatment are associated with the market's expansion. The rising demand for sophisticated therapies is driving market expansion.
The growth is attributable to the increasing occurrence of rare and life-threatening disorders, such as metabolic and ocular diseases, and increased investment in R&D of advanced therapeutic medical goods. Furthermore, ATMPs such as mesenchymal stem cells (MSCs) represent a novel treatment for the COVID-19 virus. Due to the complexity of the manufacturing process, the COVID-19 pandemic has dramatically affected the cell and gene therapy sector. Tissue engineering has significantly benefited from technological advances in recent years. This approach aids in the replacement or restoration of injured tissues and organ function.
Similarly, gene and cell therapy are attracting many patients to treat rare disorders, the prevalence of which is increasing globally. Numerous prominent players use market strategies such as technical alliances and collaborations, mergers and acquisitions, unique product debuts with approvals, R & D activities, strategic initiatives, training services, and regional expansion to build a stronghold in the market growth.
Competitive Landscape:
Some major key players in the Advanced Therapy Medicinal Products CDMO Market:
- Celonic;
- Bio Elpida;
- CGT Catapult;
- Rentschler Biopharma SE;
- AGC Biologics;
- Catalent;
- Lonza;
- WuXi Advanced Therapies;
- BlueReg;
- Minaris Regenerative Medicine;
Market Segmentation:
The Advanced Therapy Medicinal Products CDMO market is segmented on the product, phase, and indication. Based on product, the market is segmented into gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold). Based on phase, the Advanced Therapy Medicinal Products CDMO are segmented into phases I, II, III, and IV. Based on the indication, the Advanced Therapy Medicinal Products CDMO are segmented into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others.
Based on product, the gene therapy segment is accounted as a significant contributor to the Advanced Therapy Medicinal Products CDMO market
Based on product, the market is segmented into gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold). The gene therapy segment is expected to account for the highest share of the market. The rapid expansion of the segment can be ascribed to therapeutic breakthroughs since the treatment can alter and improve genetics or modify the targeted treatment. Another aspect driving expansion is increased awareness, which leads to patients wanting this therapy even during the clinical stages. Gene therapy has seen rapid expansion in recent years because of its effectiveness in penetrating cells and beginning genetic materials.
The oncology segment witnessed growth at a rapid rate
Based on the indication, the Advanced Therapy Medicinal Products CDMO are segmented into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others. The oncology segment dominated the market. The increasing incidence of cancer and chronic diseases due to the growing elderly population is contributed to the segment's growth. Oncology is a medical speciality that diagnoses and treats cancer. ATMPs were first used to find a breakthrough in cancer treatment, and as a result, this segment has seen the most expertise and effort over the years.
The North American Advanced Therapy Medicinal Products CDMO market holds a significant regional revenue share
The North American Advanced Therapy Medicinal Products CDMO market is expected to register the highest market share in revenue shortly. The region is expected to account for the significant share of market revenue. North America's market relevance is achievable due to rising awareness of advanced therapy and expanding outsourcing operations. In addition, the United States has been a pioneer in R&D operations to provide new treatments to the healthcare business. As a result of these factors, the market is expected to grow at a rapid pace in the approaching years. In addition, Asia Pacific is projected to expand rapidly in the global Advanced Therapy Medicinal Products CDMO market because of developments in treatment technology and increased outsourcing activity in the region. The leading competitors in the advanced therapy medicinal products CDMO market are working hard to meet the region's need for advanced therapy therapeutic goods.
Recent Developments:
- In May 2024, Siren Biotechnology and Catalent Inc. established a strategic agreement to aid in the advancement and manufacturing of Siren Biotechnology's AAV immuno-gene treatments. Siren Biotechnology is renowned for its pioneering Universal AAV Immuno-Gene Therapy for Cancer, whereas Catalent Inc. is a prominent global facilitator of the development and dissemination of enhanced treatments for patients worldwide.
Advanced Therapy Medicinal Products CDMO Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 5.88 Billion |
|
Revenue forecast in 2031 |
USD 14.58 Billion |
|
Growth rate CAGR |
CAGR of 12.12% from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
Product, Phase, Indication |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Celonic; Bio Elpida; CGT Catapult; Rentschler Biopharma SE; AGC Biologics; Catalent; Lonza; WuXi Advanced Therapies; BlueReg; Minaris Regenerative Medicine; Patheon. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
